Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2020

01-06-2020 | Chronic Lymphocytic Leukemia | Editorial

A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas

Authors: S. Ramón y Cajal, P. Sancho, L. Soucek, H. Peinado, M. Abad, M. Valiente, A. Efeyan, J. Pardo, V. Quesada, J. Jimeno, P. M. Duque, A. Antón, I. Varela, A. J. Schuhmacher

Published in: Clinical and Translational Oncology | Issue 6/2020

Login to get access

Excerpt

Over the last years, there have been relevant advances in cancer research and in treatment based on specific genetic alterations improving survival in some tumors. Nevertheless, progress is still dismal in most carcinomas when are disseminated with metastasis; the survival is less than 30% in most cases. Then, we need to move forward looking for new paradigms which may explain the complex mechanisms involved in carcinogenesis and in new treatment approaches. …
Metadata
Title
A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas
Authors
S. Ramón y Cajal
P. Sancho
L. Soucek
H. Peinado
M. Abad
M. Valiente
A. Efeyan
J. Pardo
V. Quesada
J. Jimeno
P. M. Duque
A. Antón
I. Varela
A. J. Schuhmacher
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02199-4

Other articles of this Issue 6/2020

Clinical and Translational Oncology 6/2020 Go to the issue

Correspondence

Comment on “Prognostic factors and survival in Ewing’s sarcoma treated by limb salvage surgery”

Research Article

Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer

Research Article

Detection of novel mitochondrial mutations in cytochrome C oxidase subunit 1 (COX1) in patients with familial adenomatous polyposis (FAP)

Special Article

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Research Article

Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma

Research Article

Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits